

Resource Summary Report

Generated by [SPARC SAWG](#) on Aug 9, 2026

NOD.Cg-Prkdc^{scid} Il2rg Tg(CMV-IL3.CSF2.KITLG)1Eav/MloySzJ

RRID:IMSR_JAX:013062

Type: Organism

Proper Citation

RRID:IMSR_JAX:013062

Organism Information

URL: <https://www.jax.org/strain/013062>

Proper Citation: RRID:IMSR_JAX:013062

Description: Mus musculus with name NOD.Cg-Prkdc^{scid} Il2rg Tg(CMV-IL3.CSF2.KITLG)1Eav/MloySzJ from IMSR.

Species: Mus musculus

Synonyms: NSGS. NSG-SGM3

Notes: gene symbol note: protein kinase; DNA activated; catalytic polypeptide|interleukin 3|transgene insertion 1; CJ Eaves|KIT ligand|colony stimulating factor 2|cytomegalovirus|interleukin 2 receptor; gamma chain; mutant strain|congenic strain: Prkdc|IL3|Tg(CMV-IL3;CSF2;KITLG)1Eav|KITLG|CSF2|CMV|Il2rg

Affected Gene: protein kinase; DNA activated; catalytic polypeptide|interleukin 3|transgene insertion 1; CJ Eaves|KIT ligand|colony stimulating factor 2|cytomegalovirus|interleukin 2 receptor; gamma chain

Genomic Alteration: severe combined immunodeficiency|transgene insertion 1; CJ Eaves|targeted mutation 1; Warren J Leonard

Catalog Number: JAX:013062

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Prkdc^{scid} Il2rg Tg(CMV-IL3.CSF2.KITLG)1Eav/MloySzJ

Record Creation Time: 20250513T053723+0000

Record Last Update: 20260808T050928+0000

Ratings and Alerts

- Used for stem cell-derived cell line by the Human Islet Research Network community. Contact(s): Michael Brehm, James Keck - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for NOD.Cg-Prkdc^{scid} Il2rg Tg(CMV-IL3.CSF2.KITLG)1Eav/MloySzJ.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 160 mentions in open access literature.

Listed below are recent publications. The full list is available at [SPARC SAWG](#) .

Varesi A, et al. (2026) ATP2B1 expression identifies human hematopoietic stem cells with superior repopulation and self-renewal. Proceedings of the National Academy of Sciences of the United States of America, 123(19), e2604380123.

Gil KB, et al. (2026) The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells. Haematologica, 111(2), 481.

Yang Z, et al. (2026) Reprogramming the tumor microenvironment with antibody against membrane-proximal AXL to overcome immune checkpoint blockade resistance. Signal transduction and targeted therapy, 11(1).

Verboon LJ, et al. (2026) DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome-associated myeloid leukemia. Blood advances, 10(12), 4120.

Faust JR, et al. (2026) Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling. The Journal of biological chemistry, 302(5), 111390.

Warmuth L, et al. (2026) Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination. Nature communications, 17(1).

Li M, et al. (2026) Selective elimination of myeloid HIV reservoirs by targeting pro-survival pathways. The Journal of infection, 92(5), 106733.

Yu X, et al. (2026) Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity. *Signal transduction and targeted therapy*, 11(1).

Li Z, et al. (2026) Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development. *Nature communications*, 17(1).

Kandarpa M, et al. (2026) Activity of PROTAC MDM2 degrader in primary leukemia cells and PDX models. *Leukemia*, 40(5), 918.

Wang JG, et al. (2026) The long noncoding RNA Inc-FAM164A1-ACLY axis promotes pro-inflammatory responses in human primary macrophages: a systems approach. *Frontiers in immunology*, 17, 1776849.

Yang D, et al. (2026) A novel humanized immune stroma PDX cancer model for therapeutic studies. *Cancer immunology, immunotherapy : CII*, 75(4).

Spiga M, et al. (2026) TIGIT disruption rescues the antitumor activity of low avidity TCR-engineered T cells by increasing TCR signal strength. *Nature communications*, 17(1), 568.

Chakraborty S, et al. (2026) Cortisol-resistant CAR-NK cells overcome steroid-induced immunosuppression in lung cancer. *Signal transduction and targeted therapy*, 11(1).

Li YR, et al. (2026) Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma. *Research (Washington, D.C.)*, 9, 1310.

Zhang Y, et al. (2026) Comprehensive analysis of the TGF- β signaling pathway: molecular mechanisms, disease drivers, and frontiers in clinical translation. *Frontiers in immunology*, 17, 1831213.

Fujino T, et al. (2026) Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias. *Cancer discovery*.

Chen HTT, et al. (2026) Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS. *Blood*.

Paraskevopoulou V, et al. (2026) Inflammatory immune modulators of AML lung infiltration and respiratory failure. *Nature immunology*, 27(8), 1590.

Foidart P, et al. (2026) Whole-genome doubling drives immune evasion by silencing antigen presentation. *Cancer cell*, 44(7), 1418.